Information Provided By:
Fly News Breaks for February 26, 2016
CLDX
Feb 26, 2016 | 07:14 EDT
Brean Capital lowered its price target on Celldex to $24 from $31 on pessimism surrounding its cancer drug candidate Rintega. The firm removed the drug from its estimates, resulting in the lowered its price target. Brean Capital maintained its Buy rating on Celldex shares based on its cash balance, which will support is operations for the next two years, and its pipeline, which continues to progress as expected.
News For CLDX From the Last 2 Days
There are no results for your query CLDX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.